Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Memorial Sloan Kettering Cancer Center Identifier:
First received: November 1, 1999
Last updated: December 17, 2015
Last verified: December 2015

RATIONALE: New imaging procedures such as fludeoxyglucose F 18 PET scan may improve the ability to detect cancer or recurrence of cancer.

PURPOSE: Clinical trial to study the effectiveness of fludeoxyglucose F 18 PET scan in diagnosing primary or recurrent cervical cancer in patients who are undergoing surgery.

Condition Intervention
Cervical Cancer
Procedure: biopsy
Procedure: computed tomography
Procedure: positron emission tomography
Radiation: fludeoxyglucose F 18

Study Type: Interventional
Study Design: Primary Purpose: Diagnostic
Official Title: A Pilot Study of 18F-Flourodeoxyglucose Positron Emission Tomography in the Diagnosis of Primary and Recurrent Cervical Cancer

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Study Start Date: May 1998
Study Completion Date: October 2002
Primary Completion Date: October 2002 (Final data collection date for primary outcome measure)
Detailed Description:


  • Assess the feasibility of using fludeoxyglucose F 18 (FDG) positron emission tomography (PET) imaging in patients with primary or recurrent cervical cancer.
  • Investigate the ability of FDG-PET scan imaging to detect lymph node metastases in these patients.
  • Investigate the ability of FDG-PET imaging to identify locally advanced disease in early stage cervical cancers.
  • Compare FDG-PET to CT scan imaging with respect to distinguishing between postradiation pelvic fibrosis and recurrent cervical cancer.
  • Investigate the ability of FDG-PET to identify recurrent cervical cancer.

OUTLINE: This is a diagnostic study.

Patients with primary cervical cancer receive fludeoxyglucose F 18 (FDG) intravenously followed 45 minutes later with positron emission tomography (PET) imaging over 60 minutes, as well as computed tomography (CT) scan. Both diagnostic imaging techniques are to assess the abdomen and pelvis, and must be done within 2 weeks prior to surgery. Patients eligible for surgery undergo radical hysterectomy and lymphadenectomy and all specimens are evaluated for correlation with the preoperative diagnostic tests findings.

Patients with recurrent cervical cancer obtain FDG-PET scan and CT scan of the thorax, abdomen, and pelvis prior to surgical exploration for pelvic exenteration. All biopsy specimens are evaluated for correlation with diagnostic tests findings.

PROJECTED ACCRUAL: A total of 30 patients (20 patients with primary cervical cancer and 10 patients with recurrent cervical cancer) will be accrued for this study.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Must meet one of the following criteria:

    • Histologically confirmed primary invasive squamous carcinoma or adenocarcinoma of the cervix
    • History of cervical cancer suspected of being recurrent
    • Known diagnosis of recurrent cervical cancer being considered for pelvic exenteration



  • 18 and over

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • No insulin-dependent diabetes mellitus
  • No active serious infection not controlled by antibiotics
  • Must tolerate being in the scanner for the duration of the study
  • Not mentally retarded
  • No prisoners
  • Not pregnant or nursing


Biologic therapy:

  • Not specified


  • Not specified

Endocrine therapy:

  • Not specified


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00003429

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Study Chair: Steven M. Larson, MD Memorial Sloan Kettering Cancer Center
  More Information Identifier: NCT00003429     History of Changes
Other Study ID Numbers: 98-047  MSKCC-98047  NCI-G98-1452 
Study First Received: November 1, 1999
Last Updated: December 17, 2015
Health Authority: United States: Federal Government

Keywords provided by Memorial Sloan Kettering Cancer Center:
stage I cervical cancer
stage II cervical cancer
recurrent cervical cancer

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Fluorodeoxyglucose F18
Molecular Mechanisms of Pharmacological Action processed this record on October 21, 2016